Free Trial
LON:TILS

Tiziana Life Sciences (TILS) Share Price, News & Analysis

Tiziana Life Sciences logo
GBX 58.50
+4.50 (+8.33%)
(As of 10/20/2021)

About Tiziana Life Sciences Stock (LON:TILS)

Key Stats

Today's Range
45
59
50-Day Range
58.50
58.50
52-Week Range
30
195
Volume
297,127 shs
Average Volume
522,223 shs
Market Capitalization
£113.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. The company also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. It has a collaboration agreement with FHI Clinical Inc. to conduct a phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal foralumab, a human anti-CD3 monoclonal antibody. The company was incorporated in 1998 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

Receive TILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TILS Stock News Headlines

Tiziana Life Sciences Plans Share Sale with Jefferies
Top 10 AI Stocks to Buy Now
Are you ready to capitalize on the booming AI market? Our experts have identified the top 10 AI stocks set to skyrocket.
Tiziana Life Appoints Ivor Elrifi As CEO
Tiziana Life Sciences Appoints Ivor Elrifi as CEO
See More Headlines

TILS Stock Analysis - Frequently Asked Questions

Tiziana Life Sciences' stock was trading at GBX 58.50 on January 1st, 2024. Since then, TILS stock has increased by 0.0% and is now trading at GBX 58.50.
View the best growth stocks for 2024 here
.

Tiziana Life Sciences PLC (LON:TILS) released its quarterly earnings results on Wednesday, September, 30th. The biotechnology company reported ($2.60) earnings per share for the quarter, topping analysts' consensus estimates of ($4.00) by $1.40.

Shares of TILS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include Tiziana Life Sciences (TLSA), Synergy Pharmaceuticals (SGYP), Meta Platforms (META), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

Last Earnings
9/30/2020
Today
11/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£-3,595,000.00
Cash Flow
GBX 25.70 per share
Book Value
GBX 23.50 per share

Miscellaneous

Free Float
N/A
Market Cap
£113.85 million
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (LON:TILS) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners